VERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA (VRTX) Stock News
The latest VRTX headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Vertex Pharmaceuticals (VRTX) closed at $508.75, up 2.06%, outperforming the S&P 500's 0.33% gain. However, the stock has declined 2.88% over the past month. The company is scheduled to report earnings on November 2, 2026, with projected EPS of $4.84 (up 0.83% YoY) and quarterly revenue of $3.4 billion (up 10.49% YoY). Despite positive revenue growth expectations, the stock holds a Zacks Rank of #3 (Hold) with a Forward P/E of 26.52, trading at a premium to its industry average.
- Zacks Investment Research·
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Vertex Pharmaceuticals stock declined 3.07% to $506.74 on October 1, 2026, underperforming the broader market gains. Despite positive earnings forecasts with expected EPS growth of 1.25% and revenue growth of 10.43% for the upcoming quarter, the stock has fallen 6.1% over the past month. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 27.73, trading at a premium to its industry average.
- Zacks Investment Research·
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex Pharmaceuticals reported Q2 2026 earnings that missed EPS estimates ($4.73 vs $4.79 consensus) but beat revenue expectations ($3.33B vs $3.23B consensus). The company raised full-year 2026 revenue guidance to $13.10-$13.20B. However, analyst estimates have trended downward over the past month despite the stock gaining 14.4%. The company received a Zacks Rank #3 (Hold) rating with a VGM Score of D, suggesting in-line returns ahead.